Key points
- Wegovy 7.2 mg is now licensed in the EU and available in Irish pharmacies, including Healthwave.
- It is a higher maintenance dose for adults with obesity, not a starting dose. You can only move up to it after at least 4 weeks on 2.4 mg.
- In the STEP UP trial, people on 7.2 mg lost about 21% of their body weight on average, compared with about 18% on 2.4 mg.
- The 7.2 mg dose comes in single-dose pens with a built-in, hidden needle: one pen each week, 4 pens in a pack.
- At Healthwave, a pack of 4 Wegovy 7.2 mg pens (a month's supply) costs €380.
Updated October 2026
When we first published this article, the higher dose was still waiting for an EU decision. That decision has now been made, the 7.2 mg single-dose pen has been approved, and Irish pharmacies have stock. We have rewritten the article to explain who the higher dose is for, what the trial evidence shows, and how to get it.
Is Wegovy 7.2 mg available in Ireland?
Yes. The European Commission approved the 7.2 mg once-weekly maintenance dose in February 2026, following a positive opinion from the EMA's medicines committee (CHMP) in December 2025. At first, the 7.2 mg dose had to be given as three 2.4 mg injections in one sitting.
On 15 July 2026 the European Commission also approved a 7.2 mg single-dose pen, so the full dose is now one injection. Novo Nordisk has since launched it to Irish pharmacies. Healthwave stocks it, and you can see the current price on our Wegovy page and our prescription price list.
Who is the higher dose for?
The 7.2 mg dose is licensed for adults living with obesity. It is a step up from the standard 2.4 mg maintenance dose, not a new way to start treatment. Everyone still begins at 0.25 mg and moves up through the usual dose schedule to 2.4 mg.
After at least 4 weeks on 2.4 mg, your prescriber can decide to increase the dose to 7.2 mg once weekly. It is usually considered for people whose weight loss has slowed or stopped on 2.4 mg, even with good diet, activity and adherence. Many people continue to do well on 2.4 mg and have no reason to change.
This is a medical decision. Your prescriber will weigh the extra benefit against the higher chance of side effects, and will take your other conditions and medicines into account.
How much more weight loss does 7.2 mg give?
The evidence comes from STEP UP, a 72-week trial of 1,407 adults with obesity (BMI 30 or more) who did not have diabetes. Participants took semaglutide 7.2 mg, semaglutide 2.4 mg or a placebo once a week, together with diet and activity advice. The results were published in The Lancet Diabetes & Endocrinology in 2025.
| After 72 weeks | 7.2 mg | 2.4 mg | Placebo |
|---|---|---|---|
| Average weight loss (taken as planned) | 20.7% | 17.5% | 2.4% |
| Lost 25% or more of body weight | 33.2% | 16.7% | 0% |
| Altered skin sensation (dysaesthesia) | 22.9% | 6.0% | 0.5% |
When the results include everyone who started the trial, including people who stopped treatment early, average weight loss was 18.7% on 7.2 mg and 15.6% on 2.4 mg. Either way, the extra benefit of the higher dose is real but moderate: about 3 percentage points more weight loss on average.
Thinking about stepping up from 2.4 mg?
Ask the doctor who prescribes your Wegovy whether 7.2 mg is right for you. If they agree, your prescription can be sent straight to Healthwave by Healthmail, and we dispense and deliver nationwide, usually within 1-3 working days.
What side effects should I expect on 7.2 mg?
The side effects are the same kind as on lower doses, but some are more common. In STEP UP the most common were stomach and bowel effects such as nausea, vomiting, diarrhoea and constipation. Most were mild to moderate and became less frequent over time.
One effect stood out at the higher dose: dysaesthesia, an altered skin sensation such as tingling, burning or skin sensitivity. It was reported by more than 1 in 5 people on 7.2 mg (22.9%), compared with 6.0% on 2.4 mg. In the trial it usually went away on its own or after the dose was reduced. Tell your prescriber if you notice it, especially if it is troublesome.
Never stop or change your dose on your own. If side effects are a problem, speak to your prescriber, who may suggest going back to 2.4 mg.
Get medical help if you have
- Severe stomach pain that does not go away, with or without vomiting. This can be a sign of pancreatitis.
- Pain in the upper right of your abdomen, fever, or yellowing of your skin or eyes.
- Vomiting or diarrhoea that stops you keeping fluids down.
- Swelling of the face, lips or throat, or difficulty breathing.
You can report a suspected side effect to the HPRA through their online reporting form.
How is the 7.2 mg pen different?
The lower doses (0.25 mg to 2.4 mg) use the FlexTouch pen, which holds 4 weekly doses and needs a new needle for each injection. The 7.2 mg dose uses a different pen: a single-dose pre-filled pen that you use once and then throw away. Each pack has 4 pens, one for each week.
The 7.2 mg pen gives a fixed dose, so there is nothing to dial. The needle is built in and hidden, so you do not need to attach or remove separate needles. Before this pen, a 7.2 mg dose meant three separate 2.4 mg injections each week. Now it is one injection, once a week, on the same day each week. Store unused pens in the fridge (2°C to 8°C), do not freeze them, and dispose of used pens in a sharps bin.
How much does Wegovy 7.2 mg cost in Ireland?
At Healthwave, a pack of 4 Wegovy 7.2 mg single-dose pens (a month's supply) costs €380. For comparison, 2.4 mg costs €295 a month. Wegovy is not covered by the medical card or the Drugs Payment Scheme, so it is a private prescription. Prices can change, so check our prescription price list for the current price.
If you are also following the oral version, see our article on when the Wegovy pill will be available in Ireland.
FAQs
Can I start Wegovy on 7.2 mg?
No. Everyone starts at 0.25 mg and increases step by step to 2.4 mg. A move to 7.2 mg is only possible after at least 4 weeks on 2.4 mg, and only if your prescriber decides it is right for you.
Do I need a new prescription for 7.2 mg?
Yes. The dose is part of the prescription, so your prescriber needs to issue a new one for 7.2 mg.
Is 7.2 mg licensed for people who are overweight but not obese?
No. The 7.2 mg dose is licensed for adults with obesity. Your prescriber will check whether it applies to you.
Can I go back to 2.4 mg?
Yes, if your prescriber advises it. Some people move back to 2.4 mg because of side effects.
Do I need to buy needles for the 7.2 mg pen?
No. Each 7.2 mg pen has its own built-in, hidden needle, so there are no separate needles to buy or attach.
Already have a prescription?
Ask your doctor to send it to healthwave.dundrum@healthmail.ie by Healthmail. We will confirm your order, pack it discreetly in cold-chain packaging and deliver nationwide.
Sources
- Wharton S, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 2025. doi:10.1016/S2213-8587(25)00226-8.
- European Medicines Agency, Wegovy: EPAR and product information, accessed October 2026.
- Novo Nordisk, European Commission approval of the Wegovy pill and the 7.2 mg pen, 15 July 2026.
- Novo Nordisk, European Commission approves the 7.2 mg dose of Wegovy, February 2026.
- Novo Nordisk Ireland, Wegovy 7.2 mg pre-filled pen information for healthcare professionals, October 2026.
- Medicines and Healthcare products Regulatory Agency (MHRA), Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
- HPRA: report a side effect of a medicine for human use.